Alongside Gilde Healthcare Partners, new investor Ventech participated in an £11.4m financing round. Current backers Entrepreneurs Fund, Quest for Growth and Solon Ventures also participated.
The proceeds of the financing will be used to progress the Prosonix’s emerging proprietary product pipeline of mono- and multi-component combination therapies, and to fund Phase 2 Clinical trials as required.
Oxford-based Prosonix’s patented particle-engineering technology is said to provide an opportunity to develop novel and generic mono and combination respiratory medicines in a range of metered dose and dry-powder inhalers.
As part of the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join the Prosonix board of directors.
Red Bull makes hydrogen fuel cell play with AVL
Formula 1 is an anachronistic anomaly where its only cutting edge is in engine development. The rules prohibit any real innovation and there would be...